FDA clears Boston Scis Renegade HI-FLO for embolisms

TriMed Staff | | Health Imaging | Practice Management
The FDA has approved Boston Scientific’s Renegade HI-FLO Fathom system for selective access and delivery of diagnostic, embolic and therapeutic materials to the peripheral vasculature.

According to company, the Renegade HI-FLO is intended for use by interventional radiologists to treat uterine fibroids and liver cancer. Natick, Mass.-based Boston Scientific said that the system combines turn-for-turn torque response with the Fathom-16 and the Renegade HI-FLO Microcatheter pre-loaded as a single platform, which will be adaptable to a range of embolization procedures via eight configurations.

TriMed Staff

Related Content

New protocol addresses contrast allergies in patients with suspected stroke
Do large language models help or hinder workflows related to radiology reports?
Hospital creates 'virtual reality technologist' role to support patients during interventional procedures
Telehealth visits not to blame for uptick in imaging orders, study shows
Up to half of medical organizations either already using or preparing to implement AI
Warning: Sidelined reactor could trigger medical isotope shortage

Around the web

Cardiovascular Business
New AI program delivers rapid, accurate echo video assessments

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Radiology Business
Key Medicare reimbursement and No Surprises Act updates from RSNA 2024

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

Cardiovascular Business
Philips, Mayo Clinic using AI to improve cardiac MRI technology

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.